Sökning: "rituximab"
Visar resultat 11 - 15 av 61 avhandlingar innehållade ordet rituximab.
11. Follicular lymphoma : clinical and biological factors associated with response to therapy and overall prognosis
Sammanfattning : Follicular lymphoma (FL) is a heterogeneous group of malignancies within the adaptive immune system. The clinical course is highly variable. Treatment includes different chemotherapy regimens as well as the anti-CD20 monoclonal antibody rituximab which has significantly improved the prognosis for patients with all types of B cell lymphomas. LÄS MER
12. Immunogenicity of biological therapies : frequency, predictability and clinical relevance in chronic inflammatory diseases
Sammanfattning : Over the past three decades, biologic therapies have revolutionised the treatment of chronic inflammatory diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), and anti-neutrophil cytoplasmic antibody (AAV)-associated vasculitis (AAV) and for many, are now a core component of management. However, unlike chemically synthesised smallmolecule drugs, biologicals are larger and are produced using complex processes in or from living organisms, resulting in a propensity to stimulate an unwanted immune response to itself or related proteins. LÄS MER
13. Antibody-based Cancer Immunotherapy : Personalization, response prediction and safety considerations
Sammanfattning : Antibody-based therapeutics have remarkably improved the field of immuno-oncology. Multiple monoclonal antibodies (mAbs) are approved for clinical use, and numerous antibodies are under clinical development. The scope of this thesis is to study the personalization of antibody-based immunotherapeutics and tools to predict their efficacy and safety. LÄS MER
14. Prognostic information from nonmalignant and malignant lymphocytes in follicular lymphoma in relation to therapy
Sammanfattning : Follicular lymphoma is the most common indolent lymphoma. It is composed of centrocytes and centroblasts, residing in follicles that also harbour nonmalignant immune and stroma cells. Follicular lymphoma is graded according to the World Health Organization criteria that are based on the frequency of centroblasts. LÄS MER
15. Aggressive B-cell Lymphomas : Studies of Treatment, FDG-PET Evaluation and Prognostic Factors
Sammanfattning : To improve outcome in young, high-risk lymphoma patients, treatment was intensified, adding etoposide and rituximab to standard CHOP treatment. Granulocyte-colony stimulating factor (G-CSF) enabled treatment bi-weekly. Results were promising: overall (OS) and event-free survival (EFS) 79% and 60% respectively, median follow up 27 months. LÄS MER
